ArticleFrontiers in immunology2017
Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Influence of Microbiota on NSAID Enteropathy: A Systematic Review of Current Knowledge and the Role of Probiotics.Advances in therapy · 2020Pooled it
- Neonatal administration ofmSphere · 2025Trial
- Multi-Analytical Approach for the Quality and Functional Evaluation of Probiotic Formulations: The Case of Lactobacillus acidophilus LA-5Probiotics and antimicrobial proteins · 2026Article
- Microbiome alternative treatments for hepatic encephalopathy: Reassessment of the potential use of lactose in lactase non-persistent cirrhosis patients.Canadian liver journal · 2026Article
- MicroRNA and Gut Microbiota: Tiny but Mighty-Novel Insights into Their Cross-talk in Inflammatory Bowel Disease Pathogenesis and Therapeutics.Journal of Crohn's & colitis · 2022Review
- The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson's disease?Neural regeneration research · 2021Article
- Variability in Probiotic Formulations Revealed by Proteomics and Physico-chemistry Approach in Relation to the Gut Permeability.Probiotics and antimicrobial proteins · 2020Article
- Probiotics: Versatile Bioactive Components in Promoting Human Health.Medicina (Kaunas, Lithuania) · 2020Review
- Review on the Alteration of Gut Microbiota: The Role of HIV Infection and Old Age.AIDS research and human retroviruses · 2020Review
- Article
- Comment on: "Search and Selection of Probiotics that Improve Mucositis Symptoms in Oncologic Patients: A Systematic Review.Nutrients · 2020Article
- A Combined Proteomics, Metabolomics and In Vivo Analysis Approach for the Characterization of Probiotics in Large-Scale Production.Biomolecules · 2020Article
- Article
- Gut Microbiome: Profound Implications for Diet and Disease.Nutrients · 2019Review
- Thermophysical Fingerprinting of Probiotic-Based Products.Scientific reports · 2019Article
- The Use of Defined Microbial Communities To Model Host-Microbe Interactions in the Human Gut.Microbiology and molecular biology reviews : MMBR · 2019Review
- Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties.Nutrients · 2019Article
- The Epithelial Barrier Model Shows That the Properties of VSL#3 Depend from Where it is Manufactured.Endocrine, metabolic & immune disorders drug targets · 2019Article
- Probiotics as a Potential Immunomodulating Pharmabiotics in Allergic Diseases: Current Status and Future Prospects.Allergy, asthma & immunology research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVariability in probiotics manufacturing may affect their properties, with potential implications for their efficacy and safety. This is of particular concern with probiotic products destined for use in patients with serious medical conditions, including human immunodeficiency virus (HIV) infection. The purpose of the study was to carry out a series of experiments comparing the properties of the US-made probiotic formulation originally commercialized under the brand name VSL#3
methodsEleven subjects receiving combined antiretroviral therapy for HIV-1 were treated for 6 months with the US-made VSL#3 formulation. At baseline and 6 months, T-cells were analyzed for phenotype and activation markers, and fecal samples were analyzed for bifidobacteria, lactobacilli, and their metabolites. The fecal metabolome was assessed using
resultsAt 6 months, fecal samples showed a significant increase in the specific bacterial genera contained in the probiotic supplement. Immune activation was reduced as shown by a significant reduction in the percentage of CD4
conclusionOur data, in conjunction with previously published findings, confirm that the new Italian-made formulation of VSL#3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.